Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Foster versus Symbicort on lung impedance and exhaled nitric oxide in asthma
2008-005707-26Phase 4Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Dec 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of beclometasone dipropionate + formoterol and budesonide in asthma (2 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoints: Lung impedance/reactance (Xrs) after 4 weeks and Exhaled nitric oxide after 4 weeks. Started Dec 2008; status: completed.
02
Drugs
beclometasone dipropionate + formoterolbudesonide
03
Conditions
asthma
Beyond the preview
Go deeper on 2008-005707-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005707-26.